Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis

Lara Herrero, Andrew Zakhary, Michelle GAHAN, Michelle Nelson, Belinda Herring, Andrew Hapel, Paul Keller, Maheshi Obeysekera, Weiqiang Chen, Kuo-Ching Sheng, Adam Taylor, Stefan Wolf, Shobha Broor, Lalit Dar, Suresh Mahalingam

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Dengue virus (DV) is the most widespread arbovirus, being endemic in over 100 countries, and is estimated to cause 50 million infections annually. Viral factors, such as the genetic composition of the virus strain can play a role in determining the virus virulence and subsequent clinical disease severity. Virus vector competence plays an integral role in virus transmission and is a critical factor in determining the severity and impact of DV outbreaks. Host genetic variations in immune-related genes, including the human leukocyte antigen, have also been shown to correlate with clinical disease and thus may play a role in regulating disease severity. The host's immune system, however, appears to be the primary factor in DV pathogenesis with the delicate interplay of innate and acquired immunity playing a crucial role. Although current research of DV pathogenesis has been limited by the lack of an appropriate animal model, the development of DV therapeutics has been a primary focus of research groups around the world. In the past decade advances in both the development of vaccines and anti-virals have increased in dramatically. This review summarises the current understanding of viral, vector and host factors which contribute to dengue virus pathogenesis and how this knowledge is critically important in the development of pharmaceutical interventions
Original languageEnglish
Pages (from-to)266-282
Number of pages17
JournalPharmacology Therapeutics
Volume137
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Dengue Virus
Viruses
Therapeutics
Arboviruses
Adaptive Immunity
HLA Antigens
Focus Groups
Research
Innate Immunity
Mental Competency
Disease Outbreaks
Virulence
Immune System
Vaccines
Animal Models
Infection
Pharmaceutical Preparations
Genes

Cite this

Herrero, Lara ; Zakhary, Andrew ; GAHAN, Michelle ; Nelson, Michelle ; Herring, Belinda ; Hapel, Andrew ; Keller, Paul ; Obeysekera, Maheshi ; Chen, Weiqiang ; Sheng, Kuo-Ching ; Taylor, Adam ; Wolf, Stefan ; Broor, Shobha ; Dar, Lalit ; Mahalingam, Suresh. / Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis. In: Pharmacology Therapeutics. 2013 ; Vol. 137, No. 2. pp. 266-282.
@article{c0fc667bb9eb40c3bf1c2cb0de7322c0,
title = "Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis",
abstract = "Dengue virus (DV) is the most widespread arbovirus, being endemic in over 100 countries, and is estimated to cause 50 million infections annually. Viral factors, such as the genetic composition of the virus strain can play a role in determining the virus virulence and subsequent clinical disease severity. Virus vector competence plays an integral role in virus transmission and is a critical factor in determining the severity and impact of DV outbreaks. Host genetic variations in immune-related genes, including the human leukocyte antigen, have also been shown to correlate with clinical disease and thus may play a role in regulating disease severity. The host's immune system, however, appears to be the primary factor in DV pathogenesis with the delicate interplay of innate and acquired immunity playing a crucial role. Although current research of DV pathogenesis has been limited by the lack of an appropriate animal model, the development of DV therapeutics has been a primary focus of research groups around the world. In the past decade advances in both the development of vaccines and anti-virals have increased in dramatically. This review summarises the current understanding of viral, vector and host factors which contribute to dengue virus pathogenesis and how this knowledge is critically important in the development of pharmaceutical interventions",
keywords = "Dengue Virus, Immunity, Pathogenesis",
author = "Lara Herrero and Andrew Zakhary and Michelle GAHAN and Michelle Nelson and Belinda Herring and Andrew Hapel and Paul Keller and Maheshi Obeysekera and Weiqiang Chen and Kuo-Ching Sheng and Adam Taylor and Stefan Wolf and Shobha Broor and Lalit Dar and Suresh Mahalingam",
year = "2013",
doi = "10.1016/j.pharmthera.2012.10.007",
language = "English",
volume = "137",
pages = "266--282",
journal = "Pharmacology Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

Herrero, L, Zakhary, A, GAHAN, M, Nelson, M, Herring, B, Hapel, A, Keller, P, Obeysekera, M, Chen, W, Sheng, K-C, Taylor, A, Wolf, S, Broor, S, Dar, L & Mahalingam, S 2013, 'Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis', Pharmacology Therapeutics, vol. 137, no. 2, pp. 266-282. https://doi.org/10.1016/j.pharmthera.2012.10.007

Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis. / Herrero, Lara; Zakhary, Andrew; GAHAN, Michelle; Nelson, Michelle; Herring, Belinda; Hapel, Andrew; Keller, Paul; Obeysekera, Maheshi; Chen, Weiqiang; Sheng, Kuo-Ching; Taylor, Adam; Wolf, Stefan; Broor, Shobha; Dar, Lalit; Mahalingam, Suresh.

In: Pharmacology Therapeutics, Vol. 137, No. 2, 2013, p. 266-282.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dengue Virus Therapeutic Intervention Strategies Base on Viral, Vector and Host Factors Involved in Disease Pathogenesis

AU - Herrero, Lara

AU - Zakhary, Andrew

AU - GAHAN, Michelle

AU - Nelson, Michelle

AU - Herring, Belinda

AU - Hapel, Andrew

AU - Keller, Paul

AU - Obeysekera, Maheshi

AU - Chen, Weiqiang

AU - Sheng, Kuo-Ching

AU - Taylor, Adam

AU - Wolf, Stefan

AU - Broor, Shobha

AU - Dar, Lalit

AU - Mahalingam, Suresh

PY - 2013

Y1 - 2013

N2 - Dengue virus (DV) is the most widespread arbovirus, being endemic in over 100 countries, and is estimated to cause 50 million infections annually. Viral factors, such as the genetic composition of the virus strain can play a role in determining the virus virulence and subsequent clinical disease severity. Virus vector competence plays an integral role in virus transmission and is a critical factor in determining the severity and impact of DV outbreaks. Host genetic variations in immune-related genes, including the human leukocyte antigen, have also been shown to correlate with clinical disease and thus may play a role in regulating disease severity. The host's immune system, however, appears to be the primary factor in DV pathogenesis with the delicate interplay of innate and acquired immunity playing a crucial role. Although current research of DV pathogenesis has been limited by the lack of an appropriate animal model, the development of DV therapeutics has been a primary focus of research groups around the world. In the past decade advances in both the development of vaccines and anti-virals have increased in dramatically. This review summarises the current understanding of viral, vector and host factors which contribute to dengue virus pathogenesis and how this knowledge is critically important in the development of pharmaceutical interventions

AB - Dengue virus (DV) is the most widespread arbovirus, being endemic in over 100 countries, and is estimated to cause 50 million infections annually. Viral factors, such as the genetic composition of the virus strain can play a role in determining the virus virulence and subsequent clinical disease severity. Virus vector competence plays an integral role in virus transmission and is a critical factor in determining the severity and impact of DV outbreaks. Host genetic variations in immune-related genes, including the human leukocyte antigen, have also been shown to correlate with clinical disease and thus may play a role in regulating disease severity. The host's immune system, however, appears to be the primary factor in DV pathogenesis with the delicate interplay of innate and acquired immunity playing a crucial role. Although current research of DV pathogenesis has been limited by the lack of an appropriate animal model, the development of DV therapeutics has been a primary focus of research groups around the world. In the past decade advances in both the development of vaccines and anti-virals have increased in dramatically. This review summarises the current understanding of viral, vector and host factors which contribute to dengue virus pathogenesis and how this knowledge is critically important in the development of pharmaceutical interventions

KW - Dengue Virus

KW - Immunity

KW - Pathogenesis

U2 - 10.1016/j.pharmthera.2012.10.007

DO - 10.1016/j.pharmthera.2012.10.007

M3 - Article

VL - 137

SP - 266

EP - 282

JO - Pharmacology Therapeutics

JF - Pharmacology Therapeutics

SN - 0163-7258

IS - 2

ER -